to-injector should be injected at rotating sites around the mid-lateral thigh.
Aim and firmly jab the green tip straight down (90 degree angle) against the outer thigh. The device will activate and deliver the atropine. Bunch up and hold the thigh to provide a thicker injection area in children or very thin adults. Hold the auto-injector in place for 10 seconds before removing from thigh. Once the auto-injection has been removed from the thigh, massage the injection site for several seconds. The auto-injector may be injected through clothing, but be sure any pockets at the injection site are empty. After injection the needle should be visible; if not, be sure the yellow cap is removed and repeat the steps for injection, but press harder against the thigh.
After use, using a hard surface, bend the needle back against the Atropen. Either pin the used Atropen to the victim's clothing, or show the used Atropen to the first medical personnel that is encountered. This will allow other medical personnel to see the number and dose of Atropen auto-injectors administered. Move the victim away from the contaminated area immediately. Try to locate additional medical help at this point.
Intense flushing of the face and trunk may occur 15 to 20 minutes following IM injection. This is called the 'atropine flush' and is not harmful when it occurs.
Intramuscular (IM) injection:
Inject into a large muscle mass. Aspirate prior to injection to avoid injection into a blood vessel. Intense flushing of the face and trunk may occur 15 to 20 minutes following IM injection. This is called the 'atropine flush' and is not harmful when it occurs.
Subcutaneous Administration
Inject subcutaneously taking care not to inject intradermally.
Other Injectable Administration
Intraosseous infusion:
NOTE: Atropine is not approved by the FDA for intraosseous administration.
During cardiopulmonary resuscitation, the same dosage may be given via the intraosseous route when IV access is not available.
Ophthalmic Administration
For ophthalmic use only.
Instruct patient on proper instillation of eye ointment or solution.
Do not to touch the tip of the dropper or tube to the eye, fingertips, or other surface.
Other Administration Route(s)
Endotracheal Administration:
NOTE: Atropine is not approved by the FDA for ET administration. According to ACLS and PALS guidelines, the parenteral atropine product may be administered via the ET route.
Endotracheal (ET) administration is associated with lower blood drug concentrations compared to IV administration and may be unreliable. Tracheal drug absorption may be unreliable, higher ET doses may be required.
Endotracheal (ET) administration should only be used if access to IV or intraosseous routes can not be achieved or is delayed.
The optimal dosage for ET administration has not been established.
Adults: Dilute each dose in 5 to 10 mL of sterile distilled water or 0.9% Sodium Chloride injection. Administer via the ET tube. ET drug absorption may be improved by dilution with sterile distilled water instead of 0.9% Sodium Chloride injection.
Children: After dose administration, flush the ET tube with a minimum of 5 mL 0.9% Sodium Chloride injection and follow with 5 ventilations.
STORAGE
Generic:
- Store at room temperature (between 59 to 86 degrees F)
Atreza:
- Store at room temperature (between 59 to 86 degrees F)
Atropine Care :
- Store at controlled room temperature (between |
